The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The aim of this work is to study the role of long non-coding RNAs WRAP53 and urothelial carcinoma-associated 1 (UCA1) as potential biomarkers in diagnosis of hepatocellular carcinoma.

Detailed Description
-----------------
Sample size calculation was done in department of medical statistics, Medical Research Institute, Alexandria University and the total minimal sample size was calculated. A prospective case control study will be conducted on 80 subjects divided into three groups: Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT. Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination. Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2. Patients will be recruited from the outpatient clinics and inpatient wards of Alexandria Main University Hospital and Medical Research Institute Hospital. Full informed consent will be taken from the patients and approval of the ethical committee of the Faculty of Medicine will be fulfilled. Exclusion criteria: Patients with any inflammatory diseases or other malignancies.

Official Title
-----------------
The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma, Liver Cirrhosis, Diagnoses Disease

Intervention / Treatment
-----------------
* Diagnostic Test: WRAP53, UCA-1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any subject without any of the exclusion criteria Exclusion Criteria: Patients with any inflammatory diseases or other malignancies.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Liver cirrhosis<br>Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT. | Diagnostic Test: WRAP53, UCA-1<br>* Diagnostic value of UCA-1 and WRAP53 in HCC<br>|
| Hepatocellular Carcinoma<br>Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination | Diagnostic Test: WRAP53, UCA-1<br>* Diagnostic value of UCA-1 and WRAP53 in HCC<br>|
| Control<br>Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2. | Diagnostic Test: WRAP53, UCA-1<br>* Diagnostic value of UCA-1 and WRAP53 in HCC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma | Calculating sensitivity and specifity of UCA-1 and WRAP53 to assess their diagnostic value in diagnosis of hepatocellular carcinoma | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hcc, liver cirrhosis, UCA-1, WRAP53